Evidence map›Paper›PMID 38310459›Full record

ArticleCurrent gene therapy2024

Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF.

Sunying Wang, Yan Chen, Hanghao Ma, Yuwei Wang, Manqing Luo, Xianwei Xie, Qingyong Yang, Kaijin Lin, Meihua Lin, Lin Lin and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sunying WangFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.
Yan ChenDepartment of Ultrasound, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Hanghao MaNingde People's Hospital, Ningde, China.
Yuwei WangDepartment of Management, Fujian Yirong Information Technology Corporation, Fuzhou, China.
Manqing LuoDepartment of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xianwei XieDepartment of Cardiology, Fujian Provincial Hospital, Fuzhou, China.
Qingyong YangDepartment of Internal Medicine, Jinshan Branch of Fujian Provincial Hospital, Fuzhou, China.
Kaijin LinFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.
Meihua LinFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.
Lin LinFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.
Ping ChenFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.
Qiaowen ZhengFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.
Fuqing SunFuqing City Hospital Affiliated to Fujian Medical University, Fuqing, Fuzhou, China.

Funding

Fuzhou Health Young and Middle-aged Scientific Research Project 2021-S-wq36Startup Fund for Scientific Research Fujian Medical University 2021QH1351
6 · The paper itself

Abstract

objectiveAbnormal live function tests have been identified as independent risk factors for ominous prognosis in patients with heart failure. However, most of the previous studies have failed to determine the contribution of direct bilirubin (DBIL) and indirect bilirubin (IBIL) separately. Hence, we aimed to explore whether DBIL or IBIL is correlated with the prognosis of heart failure with preserved ejection fraction (HFpEF).

methodsA total of 19837 patients were hospitalized for HFpEF between January 2012 and January 2022 in Fuqing City Hospital affiliated with Fujian Medical University. The primary endpoint was in-hospital all-cause mortality. Secondary endpoints included in-hospital cardiovascular mortality and 30-day re-admission for heart failure.

resultsUnivariable analysis indicated that patients with elevated DBIL or IBIL were exposed to a higher risk of mortality and re-admission. However, in multivariable models, both ln-transformed DBIL and TBIL, but not IBIL, were independent risk factors for in-hospital all-cause mortality (hazard ratio (HR)=1.796, 95% confidential interval (CI)=1.477-2.183, P<0.001; HR=1.854, 95% CI=1.461-2.352, P.0.001; HR=1.161, 95% CI=0.959-1.407, P=0.126) and in-hospital cardiovascular mortality (HR=1.831, 95% CI=1.345-2.492, P.0.001; HR=1.899, 95% CI=1.300-2.773, P=0.001; HR=1.145, 95% CI=0.841-1.561, P=0.389). Only DBIL remained independently associated with 30-day readmission for heart failure (HR=1.361, 95% CI=1.036-1.787, P=0.027). Adding ln-transformed DBIL to model 1 increased its discriminatory capacity (C-statistic: 0.851 to 0.869, respectively), whereas adding ln-transformed IBIL yielded little increment (C-statistic: 0.851 to 0.852, respectively).

conclusionDBIL, but not IBIL, was associated with short-term ominous prognosis in patients with HFpEF. Hence, DBIL may be the superior predictor for prognosis in HFpEF.

Indexed as

BilirubinHeart FailureAgedAged, 80 and overFemaleHumansMaleMiddle AgedPatient ReadmissionPrognosisRisk FactorsStroke VolumeBilirubindirect bilirubinHeart failure with preserved ejection fractionindirect bilirubinmortalityprognosisreadmission.

Identifiers

PMID38310459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.